Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Nivolumab

5

XII.d Myocarditis (can be fulminant)

1
Last update : 23/07/2016
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Avelumab
1
Durvalumab
3
Immune checkpoint inhibitors (ICI) - ICI combinatorial Rx
5
Lambrolizumab
4
PD-1/PD-L1-inhibitors or blocking agents/drugs
5
Pembrolizumab
5

Publications

Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis.
Investigational new drugs 2024 Feb;42;116-126 2024 Feb
Nivolumab-associated myositis myocarditis and myasthenia and anti-striated muscle antibodies.
Internal medicine journal 2020 Aug;50;1003-1006 2020 Aug
Fatal Myocarditis Following Treatment with the PD-1 Inhibitor Nivolumab.
Journal of forensic sciences 2018 May;63;954-957 2018 May
Late-Onset Fulminant Myocarditis With Immune Checkpoint Inhibitor Nivolumab.
The Canadian journal of cardiology 2018 Jun;34;812.e1-812.e3 2018 Jun
Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.
Neurology 2017 Sep 12;89;1127-1134 2017 Sep 12
Smoldering myocarditis following immune checkpoint blockade.
Journal for immunotherapy of cancer 2017 Nov 21;5;91 2017 Nov 21
Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung.
Lung cancer (Amsterdam, Netherlands) 2016 Sep;99;117-9 2016 Sep
Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer.
BMJ case reports 2016 Jul 20;2016; 2016 Jul 20

Powered by

  • ^
  • Contact
  • Cookies
  • About